Skip to main content
SpringerLink
Log in

Estrogen Receptor Phenotypes Defined by Gene Expression Profiling

  • Chapter
  • First Online:
Hormone Receptors in Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 147))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tan P, Downey T, Spitznagel E, Xu P, Fu D, Dimitrov D, et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucl Acids Res. 2003;31:5676–84.

    Article  PubMed  CAS  Google Scholar 

  2. Fan JB, Gunderson KL, Bibikova M, Yeakly JM, Chen J, Wickham Garcia E, et al. Illumina universal bead arrays. Methods Enzymol. 2006;410:57–75.

    Article  PubMed  CAS  Google Scholar 

  3. Walker SJ, Worst TJ, Vrana KE. Semiquantitative real-time PCR for analysis of mRNA levels. Methods Mol Med. 2003;79:211–27.

    PubMed  CAS  Google Scholar 

  4. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–7.

    Article  PubMed  CAS  Google Scholar 

  5. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2: 418–27.

    Article  PubMed  CAS  Google Scholar 

  6. Frasor J, Danes J, Komm B, Chang K, Lyttle CR, Katzenellenbogen B. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 2003;144:4562–74.

    Article  PubMed  CAS  Google Scholar 

  7. Frasor J, Stossi F, Danes J, Komm B, Lyttle CR, Katzenellenbogen B. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004;64:1522–33.

    Article  PubMed  CAS  Google Scholar 

  8. Fan M, Yan P, Hartman-Frey C, Chen L, Paik H, Oyer S, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006;66: 11954–66.

    Article  PubMed  CAS  Google Scholar 

  9. Oh D, Troester M, Usary J, Hu Z, He X, Fan C, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006;24:1656–64.

    Article  PubMed  CAS  Google Scholar 

  10. Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. PNAS. 2001;98:5116–21.

    Article  PubMed  CAS  Google Scholar 

  11. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor [alpha] after PKA activation in breast cancer. Cancer Cell. 2004;5:597–605.

    Article  PubMed  CAS  Google Scholar 

  12. Zhang J, Campbell R, Ting A, Tsien R. Creating new fluorescent probes for cell biology. Nat Rev Mol Cell Biol. 2002;3:906–18.

    Article  PubMed  CAS  Google Scholar 

  13. Shang Y, Hu X, DiRenzo J, Lazar M, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000;103:843–52.

    Article  PubMed  CAS  Google Scholar 

  14. Metivier R, Penot G, Hubner M, Reid G, Brand H, Kos M, et al. Estrogen receptor-[alpha] directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 2003;115:751–63.

    Article  PubMed  CAS  Google Scholar 

  15. Carroll J, Liu XS, Brodsky A, Li W, Meyer C, Szary A, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122:33–43.

    Article  PubMed  CAS  Google Scholar 

  16. Carroll J, Meyer C, Song J, Li W, Geistlinger T, Eeckhoute J, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet. 2006;38:1289–97.

    Article  PubMed  CAS  Google Scholar 

  17. Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  PubMed  CAS  Google Scholar 

  18. Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98:10869–74.

    Article  PubMed  CAS  Google Scholar 

  19. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS. 2003;100:8418–23.

    Article  PubMed  CAS  Google Scholar 

  20. Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560–9.

    Article  PubMed  CAS  Google Scholar 

  21. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262–72.

    Article  PubMed  CAS  Google Scholar 

  22. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt A, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25:1239–46.

    Article  PubMed  CAS  Google Scholar 

  23. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal L, Borg A, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001;61:5979–84.

    PubMed  CAS  Google Scholar 

  24. van’t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.

    Article  Google Scholar 

  25. van de Vijver M, He Y, van't Veer L, Dai H, Hart A, Voskuil D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.

    Article  PubMed  Google Scholar 

  26. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351: 2817–26.

    Article  PubMed  CAS  Google Scholar 

  27. Ma X, Wang Z, Ryan P, Isakoff S, Barmettler A, Fuller A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607–16.

    Article  PubMed  CAS  Google Scholar 

  28. Wang Y, Klijn J, Zhang Y, Sieuwerts A, Look M, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–9.

    PubMed  CAS  Google Scholar 

  29. Dai H, van't Veer L, Lamb J, He Y, Mao M, Fine B, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005;65:4059–66.

    Article  PubMed  CAS  Google Scholar 

  30. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003;9:2406–15.

    PubMed  CAS  Google Scholar 

  31. Creighton CJ, Osborne CK, van de Vijver M, Foekens J, Wang Y, et al. Gene expression profiles of ER+/PR– breast cancer are associated with genomic instability and Akt/mTOR signaling, and predict poor patient outcome better than clinically assigned PR status. Breast Cancer Res Treat. 2007;106:S10.

    Google Scholar 

  32. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early breast cancer trialists’ group. Lancet. 2005;365:1687–717.

    Google Scholar 

  33. Pritchard K. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res. 2003;9:460S–7S.

    PubMed  CAS  Google Scholar 

  34. Paik S, Shak S, Tang G, Kim C, Joo H, Baker J, et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. J Clin Oncol. 2005;23:16S.

    Google Scholar 

  35. Reid J, Lusa L, De Cecco L, Coradini D, Veneroni S, Daidone M, et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005;97:927–30.

    Article  PubMed  CAS  Google Scholar 

  36. Ma X, Hilsenbeck S, Wang W, Ding L, Sgroi D, Bender R, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006;24:4611–9.

    Article  PubMed  CAS  Google Scholar 

  37. Goetz M, Suman V, Ingle J, Nibbe A, Visscher D, Reynolds C, et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006;12: 2080–7.

    Article  PubMed  CAS  Google Scholar 

  38. Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol. 2007;25:662–8.

    Article  PubMed  CAS  Google Scholar 

  39. Rodriguez B, Jin V, Cheng A, Davuluri R, Gray J, Huang T. HOXB13 is an estrogen receptor responsive gene preferentially methylated in ER-positive breast cancer. AACR Meeting Abstracts. 2006;2006:377.

    Google Scholar 

  40. Wang Z, Dahiya S, Provencher H, Muir B, Carney E, Coser K, et al. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res. 2007;13:6327–34.

    Article  PubMed  CAS  Google Scholar 

  41. Loi S, Piccart MJ, Desmedt C. Prediction of early distant relapses on tamoxifen in early-breast cancer (BC): a potential tool for adjuvant aromatase inhibitors (AI) tailoring. Proc Am Soc Clin Oncol. 2005;23.

    Google Scholar 

  42. Jansen M, Foekens J, van Staveren I, Dirkzwager-Kiel M, Ritstier K, Look M, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol. 2005;23:732–40.

    Article  PubMed  CAS  Google Scholar 

  43. Kok M, Linn S, Wessels L, Jansen M, Van den Berg TM, Delahaye L, et al. Robust independent validation of the 81-gene breast cancer tamoxifen response profile. Breast Cancer Res Treat. 2006;100.

    Google Scholar 

  44. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. ATAC trialists’ group. Lancet. 2005;365:60–2.

    Google Scholar 

  45. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7: 991–6.

    Article  PubMed  CAS  Google Scholar 

  46. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 369:559–70.

    Google Scholar 

  47. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007;9:R37.

    Article  PubMed  Google Scholar 

  48. Miller W, Larionov A, Renshaw L, Anderson T, White S, Murray J, et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics. 2007;17:813–26.

    Article  PubMed  CAS  Google Scholar 

  49. Lin Z, Reierstad S, Cotteril H, Rademaker A, Khan S, Haynes B, et al. Messenger RNA levels of estrogen-related genes in malignant breast tumor tissue predict responsiveness to aromatase inhibitors. Breast Cancer Res Treat. 2006;100:S9.

    Google Scholar 

  50. Chang J, Wooten E, Tsimelzon A, Hilsenbeck S, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–9.

    Article  PubMed  CAS  Google Scholar 

  51. Hannemann J, Oosterkamp H, Bosch C, Velds A, Wessels L, Loo C, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2005;23:3331–42.

    Article  PubMed  CAS  Google Scholar 

  52. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. PNAS. 2001;98:11462–7.

    Article  PubMed  CAS  Google Scholar 

  53. Nagai MA, Da Ros N, Neto MM. Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int J Cancer. 2004;111: 892–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Medical Center, Amsterdam, The Netherlands

    Marc van de Vijver

Authors
  1. Marleen Kok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabine Linn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc van de Vijver
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc van de Vijver .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Baylor Plaza 1, Houston, 77030, U.S.A.

    Suzanne A. W. Fuqua

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kok, M., Linn, S., van de Vijver, M. (2009). Estrogen Receptor Phenotypes Defined by Gene Expression Profiling. In: Fuqua, S. (eds) Hormone Receptors in Breast Cancer. Cancer Treatment and Research, vol 147. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09463-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09463-2_11

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09462-5

  • Online ISBN: 978-0-387-09463-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation